KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $1.55.

  • Rigel Pharmaceuticals' EPS (Basic) rose 11830.99% to $1.55 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.33, marking a year-over-year increase of 265217.39%. This contributed to the annual value of $0.99 for FY2024, which is 16899.8% up from last year.
  • According to the latest figures from Q3 2025, Rigel Pharmaceuticals' EPS (Basic) is $1.55, which was up 11830.99% from $3.33 recorded in Q2 2025.
  • In the past 5 years, Rigel Pharmaceuticals' EPS (Basic) registered a high of $3.33 during Q2 2025, and its lowest value of -$0.47 during Q1 2024.
  • Over the past 5 years, Rigel Pharmaceuticals' median EPS (Basic) value was -$0.08 (recorded in 2021), while the average stood at $0.28.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' EPS (Basic) tumbled by 48750.0% in 2024, and later skyrocketed by 565000.0% in 2025.
  • Quarter analysis of 5 years shows Rigel Pharmaceuticals' EPS (Basic) stood at -$0.14 in 2021, then surged by 158.7% to $0.08 in 2022, then tumbled by 39.15% to $0.05 in 2023, then surged by 1529.44% to $0.81 in 2024, then soared by 90.25% to $1.55 in 2025.
  • Its EPS (Basic) stands at $1.55 for Q3 2025, versus $3.33 for Q2 2025 and $0.64 for Q1 2025.